T he renin-angiotensin system is a coordinated hormonal cascade of major importance in cardiovascular and renal regulation. The principle effector of this system is the octapeptide angiotensin II (Ang II), which acts at 2 cell membrane receptors, AT 1 and AT 2 . The majority of the actions of Ang II have been demonstrated to be mediated by the AT 1 receptor, including growth promotion, vasoconstriction, antinatriuresis, aldosterone secretion, salt appetite, thirst, sympathetic outflow and inhibition of renin biosynthesis, and secretion. 1 The AT 2 receptor has been less well understood. Past studies, however, clearly demonstrated that the AT 2 receptor mediates cellular differentiation and growth, opposing the actions of Ang II through the AT 1 receptor. 2 Studies in the mid to late 1990s demonstrated that AT 2 receptor stimulation engenders an autacoid vasodilator cascade composed of bradykinin (BK), nitric oxide (NO), and guanosine cyclic 3Ј, 5Ј-monophosphate (cGMP). [3] [4] [5] This discovery turned attention to the possibility that the AT 2 receptor may mediate vasodilation, opposing the vasoconstrictor actions of Ang II at the AT 1 receptor. 6 Parallel cell signaling studies indicated that the AT 2 receptor is G-proteincoupled (through Gi␣) and that receptor stimulation is accompanied by an increase in phosphotyrosine phosphatase activity and an inhibition of MAP kinase enzymes (p42 and p44) composing the extracellular signal-related kinase (ERK1/2). AT 2 receptor-mediated inhibition of the extracellular signal-regulated kinase pathway opposed the actions of Ang II, resulting in extracellular signal-regulated kinase phosphorylation via the AT 1 receptor. 1, 2, 6, 7 Work during the late 1990s through 2002 suggested that the AT 2 receptor might serve as a vasodilator counterforce to the AT 1 receptor. 2, 6, 7 However, vasorelaxation was difficult to elicit in some experimental models, attributed to the relatively low level of AT 2 receptor vascular expression compared with that of the AT 1 receptor. 1, 6 To unmask the vasodilator action of the AT 2 receptor, experiments began to focus on eliminating the vasoconstrictor action of the AT 1 receptor with an AT 1 receptor blocker before and during AT 2 receptor stimulation. These studies demonstrated that AT 2 receptor activation by Ang II clearly dilated blood vessels and reduced blood pressure. 8, 9 Studies also demonstrated that at least part of the depressor action of AT 1 receptor blockade is mediated by AT 2 receptor stimulation, in acute and chronic experimental models. 10, 11 The vasodilator action of the AT 2 receptor was easier to detect during conditions in which the renin-angiotensin system was upregulated, such as sodium restriction, Ang II infusion, or renal vascular hypertension. 6, 10, 11 Most studies pointed to the role of BK, NO, and cGMP in mediating the observed vasodilator response via the AT 2 receptor. 6, 7 So, is there anything new about the AT 2 receptor during the past 2 years? Yes, in many ways these have been "banner years" in promoting our understanding of the AT 2 receptor, validating previous observations, and elucidating new roles for the receptor in cardiovascular and renal function. 1 Studies have unequivocally confirmed the role of the AT 2 receptor as a vasodilator mediator in resistance microvessels as well as in large capacitance vessels. 2 AT 2 receptor stimulation of BK, NO, and cGMP formation is a consistent signaling pathway for vasodilation. 3 An additional cell signaling pathway, phospholipase D, has been identified for the AT 2 receptor. 4 The AT 2 receptor inhibits renin biosynthesis and release. 5 The AT 2 receptor appears to have a protective role in ischemic nephropathy. 6 The AT 2 receptor is cadioprotective after myocardial infarction and during states of Ang II excess; these beneficial responses also are mediated by BK and NO. 7 An AT 2 receptor gene polymorphism is associated with coronary disease in men.
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Vasodilation Mediated by BK, NO, and cGMP
During the past 2 years, several convincing studies have been reported confirming the vasodilator action of the AT 2 receptor. Hannan et al 12 reported that AT 2 receptors mediate vasodilation in the rat uterine artery. AT 2 receptor antagonist PD-123319 (PD) induced a 4-fold leftward shift (more sensitive) in the Ang II concentration-response curve for vascular contraction. Thus, the AT 2 receptor inhibited Ang II-induced constriction in these vessels. Because the action of PD was duplicated by the BK-B 2 receptor antagonist icatibant and independently by the NO synthase inhibitor N-nitro-Larginine, and arterial cGMP concentrations were increased by Ang II, the vasodilatory action of the AT 2 receptor was considered to be mediated by BK, NO, and cGMP. Because normal pregnancy is accompanied by enhancement of AT 2 receptor expression, 13 it is likely that the AT 2 receptor mediates counter-regulatory vasodilation in pregnancy. If this is so, then abnormalities in AT 2 receptor expression and function are candidates for vasoconstriction in pregnancyinduced hypertension (preeclampsia).
The AT 2 receptor dilates mesenteric arterial segments under flow conditions. 14 In the presence of AT 1 receptor blockade, Ang II dilated these vessels via endothelial AT 2 receptors. BK-B 2 receptor blockade substantially inhibited this response, and AT 2 receptor-mediated vasodilation was markedly reduced in kininogen-deficient Brown Norway Katholick rats compared with wild-type (WT) controls. 14 These studies demonstrate that the AT 2 receptor mediates vasodilation via local BK production in mesenteric resistance vessels in a flow-dependent manner. These observations suggest that shear stress caused by increased blood flow maybe important in AT 2 receptor-mediated vasodilation. Similarly, Bergaya et al 15 showed that to observe the contribution of the vascular kallikrein/kinin system to flowdependant dilation, functional AT 2 receptors are required. AT 2 receptor inhibition with PD decreased flow-induced dilation in WT mice, but not in mice lacking tissue kallikrein. 15 In these studies, the BK-B 2 receptor antagonist icatibant reduced the vasodilatory response to flow in WT mice, but not in mice lacking the AT 2 receptor.
Taken together, this new information strongly suggests that resistance microvessels are a major site of AT 2 receptor action. However, evidence accumulated during the past year also documents a role of AT 2 receptors in large capacitance vessels. Yayama et al 16 tested AT 2 receptor expression in the rat thoracic aorta subjected to pressure-overload by means of suprarenal abdominal aortic banding. There was a 3-fold upregulation of AT 2 receptor mRNA in the pressureoverloaded aorta 4, 7, 14, and 28 days after banding. In the pressure-overloaded vessels, Ang II constrictor responses were abrogated but were restored to control levels by AT 2 receptor antagonist PD. Removal of the endothelium nullified the differences in Ang II responsiveness previously observed between sham control and pressure-overloaded aortae. Therefore, pressure-overload of large capacitance vessels upregulates AT 2 receptor expression, which appears to limit Ang II-mediated vasoconstriction. Because renal perfusion pressure and blood flow were reduced in this model, the endogenous renin-angiotensin system was activated, which may have induced increased AT 2 receptor expression and function. In this regard, this study found that pressure-induced AT 2 receptor expression was dependent on Ang II activation of AT 1 receptors. Thus, a counter-regulatory positive feedback loop may be established wherein AT 1 receptor-induced vasoconstriction is automatically counterbalanced by AT 2 receptor upregulation and consequent vasodilation. The mechanism of AT 2 receptor-induced dilation in the pressure-overload model is BK-dependent, because the contractile response was restored with PD or icatibant in mice. 17 Ang II invoked a 9-fold increase in aortic cGMP that was abolished by either PD or icatibant. Functional vasodilator AT 2 receptors also have been demonstrated in the fetal aorta, where AT 2 receptor expression is extremely high. 18 These findings may be important in pathophysiology, because normal counter-regulatory upregulation of the AT 2 receptor in certain disease states may be rendered sluggish or inoperative, lending to unmitigated vasoconstriction.
Two studies during the past year have clarified AT 2 receptor-mediated vascular actions in the coronary circulation. Thai et al 19 found in the normal and failing rat hearts that chronic candesartan-induced coronary vasodilation was abolished with NO synthesis inhibitor N G -nitro-L-arginine methyl ester (L-NAME) or PD, which reduced acetyl choline-induced vasodilation to baseline levels. Also, in bovine pulmonary endothelial cells, candesartan increased NO synthase expression, but this was eliminated by PD. Thus, AT 1 receptor blockade induced endothelium-dependent coronary vascular relaxation that was mediated by Ang II stimulation of the AT 2 receptor. Batenburg et al, 20 studying human coronary microarteries, demonstrated that Ang II-induced contraction was prevented by AT 1 receptor blockade and potentiated by AT 2 receptor blockade. The augmentation of coronary vasoconstriction by PD was abolished by icatibant, L-NAME, or removal of the endothelium. In the presence of AT 1 receptor blockade, Ang II elicited vascular relaxation, which was eliminated by PD. These studies demonstrate functional AT 2 vasodilator receptors in the coronary microcirculation that use a BK-NO-cGMP signaling pathway. Because the expression of AT 2 receptors is quantitatively similar to that of AT 1 receptors in the human heart, 21 these findings invite further exploration of the normal physiological balance between these 2 receptors and their relative roles in cardiac pathophysiology.
The vasodilator action of AT 2 receptors may be mediated not only by BK and NO but also by inhibition of phospholipase D. 22 In preglomerular vascular smooth muscle cells from spontaneously hypertensive rat kidneys in which AT 1 receptors were expressed 3:1 over AT 2 receptors, Ang II activated phospholipase D more powerfully than in vessels from Wister Kyoto rats in which the receptor expression ratio was 1:1. Thus, AT 2 receptors inhibit the ability of Ang II to activate phospholipase D via AT 1 receptors. 22 
Inhibition of Renin Biosynthesis and Secretion
The AT 2 receptor is expressed in renal juxtaglomerular (JG) cells of the afferent arteriole. JG cell AT 1 receptors inhibit renin biosynthesis and secretion, providing a short-loop negative feedback mechanism to dampen Ang II production. 23 Angiotensin-converting enzyme inhibition and/or AT 1 receptor blockade unmask this short-loop negative feedback inhibition of renin secretion resulting in increased circulating active renin concentrations and Ang I production. AT 1 receptor blockade in JG cells increased renin secretion rate and Ang II levels in the media and reduced active, but not total, renin content. 24 The decrease in active renin content was blocked by PD. AT 2 receptor agonist CGP42112A (CGP) increased renin secretion rate and decreased active renin content, and these actions of CGP were blocked by PD. 24 These findings suggest that AT 1 receptor blockade inhibited prorennin processing in JG cells via AT 2 receptors. 24 In conscious rats, plasma renin activity and intrarenal levels of Ang II were increased by direct renal cortical 
Renal Protection
The AT 2 receptor has a protective role in the renal wrap model of angiotensin-dependent hypertension. 10 However, the more general protective role of the AT 2 receptor in the kidney has not been well-understood. AT 2 receptor transgenic (AT 2 R-Tg) and WT mice were subjected to 5/6 nephrectomy, a model of ischemic renal injury. 26 In AT 2 R-Tg mice, glomerular expression of the AT 2 receptor was upregulated by 5/6 nephrectomy. Urinary albumin excretion was decreased by approximately one-third in AT 2 R-Tg compared with WT mice. In response to 5/6 nephrectomy, AT 2 R-Tg had decreased transforming growth factor-␤ and platelet-derived growth factor, and urinary excretion of NO metabolites was increased 2.5-fold. All of these responses were abolished by the AT 2 receptor antagonist PD. 26 The 5/6 nephrectomy model develops a time-dependent increase in AT 2 receptor expression at 7, 15, and 30 days after renal ablation. 27 Animals pretreated with AT 1 receptor antagonist losartan demonstrated a further increase in AT 2 receptor expression. AT 2 receptor antagonist PD downregulated the AT 2 receptor and increased blood pressure and renal damage in this model. 27 All of these studies demonstrate that the AT 2 receptor is protective in ischemic renal injury. 10, 26, 27 
Potential Role in Renal Function
As stated, AT 2 receptor-mediated vasodilation can oppose AT 1 receptor-mediated vasoconstriction. However, the role of the AT 2 receptor in the renal microcirculation has not been investigated systematically. Duke et al 28 explored the independent contributions of AT 1 and AT 2 receptors in the control of regional kidney blood flow in the rabbit. These authors showed that under basal conditions, Ang peptides do not significantly influence medullary blood flow. In the renal cortical circulation, as in systemic microvessels, AT 2 receptor activation counteracted AT 1 receptor-mediated vasoconstriction. However, in the renal medulla, AT 1 receptor stimulation engendered vasodilation that also was opposed by AT 2 receptor activation. 28 These observations may be important in the pathogenesis of hypertension because renal medullary blood flow has been recorded as reduced in certain animal models of hypertension, 29 in which the renin-angiotensin system is activated. A paucity of studies are available on the potential actions of AT 2 receptors on renal sodium excretion. Hakan and Hussain 30 recently reported that AT 1 receptor blockade with candesartan produced natriuresis to a greater degree in obese Zucker than in lean rats. Candesartan-induced natriuresis was abolished by AT 2 receptor antagonist PD in obese, but not in lean, rats and infusion of AT 2 receptor agonist CGP-42112A induced a natriuresis to a greater extent in obese than in lean rats. AT 2 receptor protein was upregulated both at basolateral membrane and brush border sites of renal proximal tubule cells of obese but not lean rats. The results of these studies suggest that, especially under conditions leading to renal tubule upregulation of the AT 2 receptor, this receptor might play a role in renal sodium transport. However, the renal tubule actions of AT 2 receptors are far from clear and this is an area of intense future interest.
Cardioprotective Actions of AT 2 Receptors
The cardiac AT 2 receptor has been the subject of much interest during the past decade. Studies have shown that the AT 2 receptor inhibits growth of cardiac myocytes. In the failing heart, AT 1 and AT 2 receptor expression is decreased and increased, respectively. However, the precise role of the AT 2 receptor in cardiac hypertrophy and left ventricular (LV) remodeling has been controversial and may depend on the AT 1 /AT 2 receptor ratio in a physiological/pathophysiologic context-specific manner. 31 Several recent articles have helped clarify the role of the AT 2 receptor in cardiac hypertrophy and remodeling after experimental myocardial infarction (MI). Brede et al 32 studied AT 2 receptor-deficient mice after myocardial infarction, which led to increases in heart:body weight ratios and myocardial cross-sectional areas in mice lacking the AT 2 receptor (AT 2 -null) compared with WT mice. The AT 2 -null mice had downregulation of myocardial endothelial nitric oxide synthase and reduced cGMP levels. In isolated cardiomyocytes, Ang II induced endothelial nitric oxide synthase expression via AT 2 receptors, and NOS blockade abolished the antihypertrophic effects on cardiac myocytes in vivo.
Oishi et al 33 also demonstrated that AT 2 -null mice have greater cardiac remodeling/hypertrophy, systolic and diastolic dysfunction, and increased mortality after MI compared with WT mice. In contrast to the previous study, the cardioprotective role of the AT 2 receptor was independent of myocyte hypertrophy. However, both studies demonstrate cardioprotection by the AT 2 receptor after MI.
In an earlier study, Bove et al 34 had demonstrated using functional magnetic resonance imaging techniques that AT 2 receptor overexpression in the mouse heart preserves LV structure and function during LV remodeling after MI. This group of investigators has recently extended this study to demonstrate that the cardiac NO pathway is largely, if not exclusively, responsible for the beneficial effects of AT 2 receptor expression. 35 NOS inhibitor L-NAME was able to abrogate virtually all of the protective actions of cardiac AT 2 receptor overexpression after MI LV remodeling. 35 Beneficial effects of cardiac-specific AT 2 receptor overexpression included reduced LV wall thickening, decreased end-diastolicand end-systolic volume indices, and increased ejection fraction after MI compared with WT mice. These results are for the most part consonant with the work of Xu et al, 36 who demonstrated that the cardioprotective effects of AT 1 receptor activation are mediated by the AT 2 receptor, even though the AT 2 receptor may not play a role in the regulation of normal (basal) cardiac function.
Application of gene transfer technology in spontaneously hypertensive rats also has demonstrated cardioprotective actions of the AT 2 receptor. 37 Administration of a lentiviral vector encoding the AT 2 receptor resulted in cardiac AT 2 receptor overexpression without altering the expression of the AT 1 receptor. AT 2 receptor gene transfer reduced LV wall thickness and heart:body weight ratios compared with controls. It is interesting that the reduction in cardiac hypertrophy occurred in the absence of a reduction of blood pressure.
Another compelling study focused on the effects of AT 2 receptor activation on myocardial collagen deposition and fibrosis. 38 WT mice were infused with Ang II for 2 weeks, at which point prominent perivascular fibrosis of the intramuscular coronary arteries developed. However, mice selectively overexpressing AT 2 receptors in cardiac myocytes had a markedly reduced fibrotic response. Furthermore, the inhibition of perivascular myocardial fibrosis in the transgenic mice was abolished by co-administration of BK-B 2 receptor antagonist icatibant or NOS inhibitor L-NAME. The cardioprotective effect of AT 2 receptor overexpression was accompanied by increased cardiac kininogenase activity, suggesting that the BK pathway had been activated with resultant stimulation of NO production. These results have important clinical ramifications, because the beneficial action of AT 1 receptor antagonist treatment on fibrosis also may be mediated by AT 2 receptor stimulation.
The Significance of AT 2 Receptor Gene Polymorphisms
Recent evidence suggests an association in the presence of linkage for the AT 2 receptor (A1332G) and premature coronary artery disease in men. 39 Because the AT 2 receptor gene is located on the X-chromosome, hemizygotic men would have a higher probability of showing the effects of a recessively acting X-chromosome susceptibility gene than would dizygotic women. Women with the AT 2 receptor polymorphisms do not have any alteration in the frequency of coronary disease compared with those without this genetic marker. 39 These results are consistent with those of an earlier study. 40 
Conclusions and Future Directions
The AT 2 receptor is now clearly established as vasodilator receptor with the majority of studies implicating the BK-NOcGMP signaling cascade in its vasorelaxant action. The AT 2 receptor is counter-regulatory to the vasoconstrictor actions of Ang II engendered by the AT 1 receptor and may provide at least some of the hypotensive benefit of AT 1 receptor blockers in hypertension. The AT 2 receptor mainly dilates small resistance arteries, although the receptor also has a vasorelaxant action on large capacitance vessels. One remaining question is whether the vasodilator action of the AT 2 receptor can be observed chronically, as suggested by past studies. 8, 9 Another question is whether the AT 2 receptor is vasodilator in humans. If so, development of an AT 2 receptor agonist for therapeutic purposes would probably be useful.
Although the AT 2 receptor opposes the AT 1 receptor in vascular reactivity, these 2 receptors operate similarly to inhibit renin biosynthesis, processing, and secretion. We need to learn more about the signaling mechanisms involved in AT 2 receptor-induced renin inhibition and to determine whether the AT 1 and AT 2 receptors act synergistically in this action. In any case, AT 1 receptor blockade should increase renin secretion and Ang II formation, which would limit further renin generation by stimulation of the AT 2 receptor.
Evidence is mounting that the AT 2 receptor is protective against ischemic renal injury. However, the effects of the AT 2 receptor on renal function, and particularly renal sodium excretion, remain largely unknown. Most studies have been conducted in AT 2 -null mice, but these animals have increased AT 1 receptor expression, complicating interpretation. 41 These studies suggest that absence of the AT 2 receptor shifts the pressure-natriuresis curve to the right (less sensitive) and induces antinatriuretic hypersensitivity to Ang II. 42, 43 Consistent with these studies, in the renal proximal tubule cell membrane, AT 2 receptors seem to inhibit Na ϩ K ϩ ATPase activity 44 and mediate a similar inhibitory effect on bicarbonate reabsorption in this nephron segment. 45 Much more information is needed, however, on the role of AT 2 receptors in renal tubule sodium transport and renal sodium excretion.
The AT 2 receptor appears with increasing certainty to be cardioprotective, inhibiting detrimental cardiac remodeling after MI. The AT 2 receptor also inhibits coronary perivascular fibrosis in response to increased circulating Ang II. The cardioprotective effect seems to result from a combination of improved cardiac systolic and diastolic function and an inhibition of fibrosis and is mediated by NO. These observations are strong indicators that AT 2 receptor agonist therapy may be beneficial in minimizing or preventing left ventricular dysfunction after MI. A major unanswered question is whether the AT 2 receptor is important in the regulation of normal cardiac function or whether the receptor only becomes a positive factor in the presence of a cardiac insult such as MI. Also, the precise intracellular signaling mechanisms whereby the receptor exerts these actions need further clarification.
The past 2 years have witnessed major advances in our understanding of the function of the AT 2 receptor, which appears to perform important cardiovascular actions of Ang II. The stage is set for closing the gaps in our basic knowledge and determining the cardiovascular and renal actions of this receptor in humans.
